FDA expands tirzepatide indication to cardiovascular risk reduction

• by Kathryn Wighton

• August 28, 2026

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

• by Kathryn Wighton

• July 16, 2026

• 6 min

Efficacy and safety of different antithrombotic treatment regimens in patients undergoing transcatheter mitral valve repair and atrial fibrillation; A meta-analysis and systematic review

• by Fuli Zhu, Zihan Yu, Zhe He

• July 21, 2026

Left ventricular longitudinal function and hyperkinetic profile: a new echo world to explore?

• by Filipe André Gonzalez, Siddharth Dugar, Michel Slama, Filippo Sanfilippo

• August 13, 2026